Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts SYRE Hot Sheet
Join SI Premium – FREE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.36), $0.40 better than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
- Expedia (EXPE) PT Raised to $204 at Stifel
- Angel Oak Mortgage Inc (AOMR) PT Lowered to $10 at B.Riley
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
